Pricing Log in Create free account
Saturday 17 October 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.

790.74 5.60 −0.70%
Market cap
$82.0B
P/E
18.9×
Fwd P/E
16.5×
Dividend yield
0.47%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Regeneron Pharmaceuticals, Inc. (REGN) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a P/E ratio of 18.9×. Over the past ten years it has ranged from 7.3× (June 2022) to 152× (June 2015); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 17.9× 2.73%
FY2024 17.4× (28.66%)
FY2023 24.4× 37.38%
FY2022 17.8× 115.25%
FY2021 8.3× (43.98%)
FY2020 14.7× (23.92%)
FY2019 19.4× 17.50%
FY2018 16.5× (51.36%)
FY2017 33.9× (24.87%)
FY2016 45.1× (48.77%)

Quarterly newest first

Period P/E ratio Change
Jun 2026 14.9× (18.10%)
Mar 2026 18.2× 1.49%
Dec 2025 17.9× 38.30%
Sep 2025 12.9× 2.93%
42 more quarters

Against its own ten years

Low 7.3× High 152×
Ten-year median 20.4×
Current reading's percentile 48

P/E ratio against peers

Company P/E ratio
ROIV Roivant Sciences Ltd. compare n/m
MRNA Moderna, Inc. compare n/m
RVMD Revolution Medicines, Inc. compare n/m
REGN Regeneron Pharmaceuticals, Inc. 18.9×
VRTX Vertex Pharmaceuticals Incorporated compare 28.8×
ARGX argenex SE compare 29.6×
ALNY Alnylam Pharmaceuticals, Inc. compare 39.5×
RPRX Royalty Pharma PLC compare 42.3×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 62.6×
Biotechnology industry median 8.5×
Healthcare sector median 23.0×
Market median 18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on REGN